P4ADNOW’s Executive Director, @GlobalDiaBEATes, breaks down how Big Pharma games the patent system to keep prices and profits high, and how we are working to stop patent abuse to ensure more competition in the drug market and lower drug costs. Be part of this fight because

The White House announced deals with Eli Lilly and Novo Nordisk to lower prices for popular weight-loss drugs like Ozempic, Wegovy, and Zepbound. The lower prices will apply for Medicare patients and for people using the upcoming TrumpRx direct-to-consumer program when it

🗓️ Join P4AD & @T1International next Thursday for a special virtual event where people living with diabetes will share their experiences, challenges, and vision for a future where no one is priced out of the care they need. Get the link, RSVP today!: https://t.co/rzyVMCOIXW

📧 Staying current on the biggest news in drug pricing has never been easier with P4ADNOW's Week In Review! Published every Friday, our Week In Review rounds up the latest news and important conversations in drug pricing and delivers them straight to your inbox. Get in the

⚠️ The PERA Act (S.1546) would drastically expand what counts as patentable resulting in more weak patents, longer monopolies, and higher costs for patients. Congress MUST reject PERA and instead advance patent reform that increases competition and saves money for patients and

Las farmacéuticas quieren debilitar la histórica negociación de precios de Medicare con el proyecto de ley EPIC, una propuesta hecha a su medida para mantener precios altos y proteger sus ganancias. Es hora de defender esta victoria para los pacientes.

Doctor @reshmagar puts it clearly: new biotechnology discoveries will be of no use to patients if they are unable to afford them. Under the 2022 prescription drug law, Medicare for the first time can negotiate lower drug prices. Medicare’s ability to negotiate can help ensure

The FDA announced a new draft guidance to speed lower-cost biosimilars to market, the Senate HELP committee held a hearing on U.S. biotechnology, and Cigna announced plans to eliminate prescription drug rebates — but will it actually deliver savings for patients?. Read more at

“Expediting the biosimilar approval process – by cutting unnecessary red tape and streamlining duplicative clinical trials – will help speed lower-cost treatments … delivering relief to patients” more from @P4ADNOW on recent @FDA action:

🚮 CONGRESS MUST TAKE OUT THE TRASH! 🚮 The EPIC Act is a pharma-backed bill in Congress that would allow drug companies to keep prices high by avoiding price negotiation for small-molecule drugs for 13 years – 4 more years than current law. Send a letter to your representative

Rather than strengthening Medicare negotiation, bills have passed to further exempt or delay negotiation for even more drugs approved for rare diseases. For example, price negotiations for Jakafi, approved for rare bone marrow cancer and other non-rare blood conditions, are

Following today’s announcement from the Food and Drug Administration (FDA) regarding new draft guidance aimed at accelerating biosimilar approvals, Merith Basey, Executive Director of Patients For Affordable Drugs Now, issued the following statement.

ORPHAN Cures Act is more expensive and harmful than originally projected and Big Pharma’s greed is not stopping there, PhRMA spent nearly $30 million on lobbying so far this year, and new I-MAK survey shows how high cost of drugs affects everyone. Read more at our Week in Review:

Did you know that PhRMA spent 3x more than an average NFL player’s salary lobbying in Washington over the last 3 months? That’s right. $9 million spent during Q3, all to ensure they can keep charging patients whatever they want while 1 in 3 Americans are struggling to afford

💊 Allowing the price of small molecule drugs to be negotiated after 9 years (instead of the 13 years proposed in the harmful EPIC Act) helps patients across the US access the medications they need at a cost they can afford. Two thirds of Americans, regardless of political

“The ORPHAN Cures Act is a wildly expensive handout to Big Pharma that will harm patients, drain taxpayer dollars, and weaken the government’s ability to rein in high drug prices,” said Merith Basey, Executive Director of Patients For Affordable Drugs Now. 💰 The CBO now

The CBO just re-scored the pharma-backed ORPHAN Cures Act — and it’s even worse than we thought. Now estimated to cost taxpayers $8.8 billion (originally $5B), the bill would exempt blockbuster drugs like Keytruda, Brukinsa, and Jakafi from Medicare negotiation — sending

AstraZeneca strikes new TrumpRx deal, CMS prepares to announce the maximum fair prices for the second round of Medicare drug negotiations, and Big Pharma’s claims exposed. Read more at Week in Review: https://t.co/k1CCcO4cl2

🚨 The EPIC Act would allow drug companies to avoid price negotiation for small-molecule drugs (which account for nearly 90% of prescription drugs in the market) for 4 additional years, so they can squeeze even more money out of patients. Two thirds of Americans, regardless of

🧟‍♂️ Big Pharma abuse of the patent system is downright haunting and bills like the PERA Act (S.1546) and the PREVAIL Act (S.1553) are even scarier! PERA, a Big Pharma giveaway that will drive up drug prices, would drastically expand what counts as patentable resulting in more

⚠️ The PERA Act (S.1546) would drastically expand what counts as patentable resulting in more weak patents, longer monopolies, and higher costs for patients. Congress MUST reject PERA and instead advance patent reform that increases competition and saves money for patients and